Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level

  • Authors:
    • Joanna Waligórska‑Stachura
    • Nadia Sawicka‑Gutaj
    • Maciej Zabel
    • Mirosław Andrusiewicz
    • Paweł Gut
    • Agata Czarnywojtek
    • Marek Ruchała
  • View Affiliations

  • Published online on: February 10, 2017     https://doi.org/10.3892/ol.2017.5713
  • Pages: 2437-2441
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Survivin and its splice variants DEx3 and 2B are involved in pathogenesis of numerous types of cancer. Proliferating cell nuclear antigen (PCNA) level correlates with cellular proliferation. The present study aimed to analyze the potential utility of survivin and its splice variants DEx3 and 2B as biomarkers for thyroid cancer. PCNA, survivin and its splice variants DEx3 and 2B expressions were analyzed in 22 tissue samples (15 thyroid cancers and 7 benign lesions) by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry (IHC). There was significantly higher staining for survivin (P=0.019), survivin DEx3 (P=0.001), survivin 2B (P=0.0149) and PCNA (P=0.0237) in thyroid malignant tumors when compared with benign lesions. The receiver operating characteristics curve analysis has shown that the cut‑off points of survivin IHC expression >2 [sensitivity 46.7%; specificity 100%; area under curve (AUC) 0.810; P=0.0005] and survivin DEx3 IHC expression >0 (sensitivity 86.7%; specificity 100%; AUC 0.933; P<0.0001) were the best predictors of thyroid malignancy. Additionally, PCNA staining >1 (sensitivity 93.3%; specificity 71.4%; AUC 0.790; P=0.0243) and survivin 2B >2 (sensitivity 46.7%; specificity 100%; AUC 0.824; P=0.0002) were the best predictors of thyroid cancer. In conclusion, the present study exhibited that survivin DEx3 expression has high specificity and sensitivity for discrimination between benign thyroid lesions and cancers. Survivin DEx3 may be considered a biological marker of thyroid malignancy and therefore applied in clinical practice.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Waligórska‑Stachura J, Sawicka‑Gutaj N, Zabel M, Andrusiewicz M, Gut P, Czarnywojtek A and Ruchała M: Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level. Oncol Lett 13: 2437-2441, 2017
APA
Waligórska‑Stachura, J., Sawicka‑Gutaj, N., Zabel, M., Andrusiewicz, M., Gut, P., Czarnywojtek, A., & Ruchała, M. (2017). Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level. Oncology Letters, 13, 2437-2441. https://doi.org/10.3892/ol.2017.5713
MLA
Waligórska‑Stachura, J., Sawicka‑Gutaj, N., Zabel, M., Andrusiewicz, M., Gut, P., Czarnywojtek, A., Ruchała, M."Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level". Oncology Letters 13.4 (2017): 2437-2441.
Chicago
Waligórska‑Stachura, J., Sawicka‑Gutaj, N., Zabel, M., Andrusiewicz, M., Gut, P., Czarnywojtek, A., Ruchała, M."Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level". Oncology Letters 13, no. 4 (2017): 2437-2441. https://doi.org/10.3892/ol.2017.5713